Drug
Mgcd0103 Docetaxel
Mgcd0103 Docetaxel: highest development phase Phase 1, developed by Mirati Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGCD0103 & Docetaxel NCT00511576 | Phase 1 | Breast Cancer |
Latest
No recent events.
Follow Mgcd0103 Docetaxel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.